Yalla Group Limited (formerly known as “FYXTech Corporation”), through its wholly-owned subsidiaries, operates a voice-centric social networking and entertainment platform, mainly in the MENA region. The platform allows individual users free access to the basic functions on the platform. It also provides enhanced experiences for individual users by sales of virtual items and provision of upgrade services on the platform. One of Yalla’s offerings is Yalla Ludo, a chatroom feature in a board game app.

Live Ventures Incorporated is a holding company that, until 2015, focused on providing online marketing solutions for small and medium business. In 2015, the Company changed its focus, acquiring purportedly profitable business in various industries that have demonstrated a strong history of earnings power.

Iterum Therapeutics plc is a clinical-stage pharmaceutical company that engages in developing antiinfectives for multi-drug resistant pathogens in Ireland and the U.S. The Company is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of, among other medical issues, uncomplicated urinary tract infections (“uUTIs”). In November 2020, Iterum submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uUTIs in patients with a quinolone non-susceptible pathogen.

This action stems from a proposed transaction announced on May 28, 2021, pursuant to which Bowl America, Inc. will be acquired by Bowlero Corp.  On July 13, 2021, Defendants filed a proxy statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction.

Activision Blizzard purports to be one of the world's largest video game publishers.

Zymergen Inc. uses a process it calls “biofacturing” to create products that purportedly combine the design and manufacturing efficiency of biological processes with technology’s ability to rapidly iterate and control diverse functions. Its first product is called Hyaline, an optical film designed for electronic companies to use for display touch sensors, which will purportedly enable customers to make foldable touchscreens and high density flexible printed circuits. Hyaline was launched in December 2020 but has not generated revenue because it is still in its qualification process with customers. On March 23, 2021, the Company filed its Registration Statement on Form S-1 with the SEC, which forms part of the Registration Statement. On April 21, 2021, the Company filed its final amendment to the Registration Statement with the SEC on Form S-1MEF, which forms part of the Registration Statement. The Registration Statement was declared effective the same day. On April 23, 2021, the Company filed its prospectus on Form 424B4 with the SEC, which forms part of the Registration Statement. In the IPO, the Company sold approximately 18,549,500 shares of common stock at a price of $31.00 per share.

Concho Resources Inc. ("Concho" or "the Company") was an independent oil and natural gas company engaged in the acquisition, development, exploration, and production of oil and natural gas properties, primarily in the Permian Basin of West Texas and Southeast New Mexico. In January 2021 ConocoPhillips acquired Concho in an all-stock transaction valued at $9.7 billion. ConocoPhillips is named in the Complaint as the successor-in-interest to Concho.

Ardelyx Inc. is a biotechnology company focused on the development of therapies for cardiorenal disorder. Though Ardelyx’s lead product candidate, tenapanor, has been approved by the FDA as a treatment for irritable bowel syndrome associated constipation, the Company has not commercialized it in the United States nor generated any revenue from its sale. Rather, Ardelyx has focused on advancing another indication for the drug, namely for helping to control serum phosphorus in adult CKD patients on dialysis.

AdaptHealth Corp., f/k/a DFB Healthcare Acquisitions Corp. ("DFB"), provides home healthcare equipment, medical supplies, and home and related services in the U.S. DFB was a SPAC, also known as a blank check company, incorporated for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. On July 8, 2019, DFB announced that it had entered into a definitive agreement for a business combination with Legacy AdaptHealth, the third largest distributor of home medical equipment ("HME") in the U.S. Upon the closing of the Merger, DFB renamed itself “AdaptHealth Corp.” and its Class A common stock began trading on the NASDAQ under the ticker symbol “AHCO.”

Oatly Group AB describes itself as the world’s original and largest oatmilk company. Oatly was founded in 1994, and its current holding company was incorporated in accordance with Swedish law on October 5, 2016, under the name Goldcup 13678 AB. On December 21, 2016, Oatly changed its name to Havre Global AB and on March 1, 2021, it changed its name to Oatly Group AB. Oatly held its U.S. IPO on or around May 20, 2021, offering and selling 84,376,000 ADSs (including 19,688,000 from certain “selling shareholders”) at a price of $17 per share. Each ADS represents one Oatly ordinary share. The IPO raised $1.4 billion for the Company.

Piedmont Lithium Inc. engages in the exploration and development of resource projects. Of particular note, the Company primarily holds a 100% interest in a lithium project covering 2,322 acres in the North Carolina. Piedmont American Depositary Shares (“ADSs”) were listed on the NASDAQ under the ticker symbol “PLLL” until December 2018. On May 17, 2021, in connection with Piedmont’s redomiciliation from Australia to the United States, Piedmont’s ADS holders received one share of Piedmont common ctock for each ADS.

Coinbase Global, Inc. is a cryptocurrency exchange. On April 14, 2021, Coinbase went public through a direct offering, making available 114,850,769 shares of its Class A common stock to the general public.

CorMedix Inc. is a biopharmaceutical company that focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the U.S. and internationally. The Company is focused on developing its lead product candidate, DefenCath, a purported novel antibacterial and antifungal solution designed to prevent costly and dangerous catheter-related bloodstream infections ("CRBSIs").

BlueCity Holdings Limited operates a platform for the LGBTQ community primarily under the BlueCity brand in China, India, Korea, Thailand, and Vietnam. The Company operates a mobile application, Blued, together with other products and services. The Company’s LGBTQ platforms provide products and services, including social and entertainment, online health consulting and online pharmacy, and assisted reproductive technology service. On June 16, 2020, BlueCity filed a registration statement on Form F-1 with the SEC in connection with the IPO, which, after amendment, was declared effective on July 7, 2020.

RenovaCare, Inc. is a development stage company that has not generated any revenue since its inception and has no commercialized products. Its activities primarily consist of research and development, business development, and capital raises. It owns the CellMist System, which consists of a treatment method for cell isolation for the regeneration of human skin cells and other tissues (the CellMist Solution) and a solution sprayer device to deliver cells to the treatment area (the SkinGun).

On October 7, 2020, Stable Road and Momentus – a private commercial space company – issued a joint press release announcing that Stable Road had agreed to acquire Momentus in a proposed merger, subject to shareholder approval. The press release stated that the merger would "create the first publicly traded space infrastructure company at the forefront of the new space economy."

360 DigiTech, Inc. through its subsidiaries, operates a digital consumer finance platform under the 360 Jietiao brand in the PRC. Its platform provides online consumer finance products to the borrowers funded by institutional funding partners. The Company also provides incremental credit assessment, collection, and other services, as well as guarantee for defaulted loans. The Company was formerly known as 360 Finance, Inc. and changed its name to 360 DigiTech, Inc. in September 2020.

Full Truck Alliance Co. Ltd. ("FTA") purports to, with its subsidiaries, operate a digital freight platform that connects shippers with truckers to facilitate shipments in the People’s Republic of China (“PRC”). It offers freight listing, matching, and brokerage services; and online transaction services, as well as various value-added services. Yunmanman and Huochebang were founded in 2013 and 2011, respectively, and both companies were digital freight platforms in the PRC prior to their merger which created FTA in 2017.

Kanzhun Limited operates an online recruitment platform, BOSS Zhipin, which is a mobile-native product that promotes instant direct chats between employers and job seekers, delivers matching results, and is powered by proprietary artificial intelligence (“AI”) algorithms and big data insights.

Orphazyme A/S is a biopharmaceutical company that develops therapies for the treatment of neurodegenerative orphan diseases. The Company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Orphazyme conducts its U.S. operations through its whollyowned subsidiary, Orphazyme US, which is focused on U.S. regulatory review and preparing for the Company’s first potential U.S. commercial launch, including legal, commercial, finance, advocacy relations, regulatory, and medical affairs functions. Orphazyme’s lead drug candidate is arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C (“NPC”), Amyotrophic Lateral Sclerosis (“ALS”), and Inclusion Body Myositis (“IBM”).